Nanomedicine for cancer patient-centered care

Abstract

Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low-toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient’s tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine-based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Several nanoformulations are currently in clinical trials, and some have been approved and marketed. However, their large-scale production and use are still hindered by an in-depth debate involving ethics, intellectual property, safety and health concerns, technical issues, and costs. Here, we survey the key approaches, with specific reference to organ-on chip technology, and cutting-edge tools, such as CRISPR/Cas9 genome editing, through which nanosystems can meet the needs for personalized diagnostics and therapy in cancer patients. An update is provided on the nanopharmaceuticals approved and marketed for cancer therapy and those currently undergoing clinical trials. Finally, we discuss the emerging avenues in the field and the challenges to be overcome for the transfer of nano-based precision oncology into clinical daily life.

Keywords

drug delivery systems / nanomedicine / nanotechnology / personalized cancer treatments / precision oncology / targeted therapy

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Feynman RP. There’s plenty of room at the bottom. Eng Sci. 1960; 23(5): 22-36.

[3] ‘Plenty of room’ revisited. Nat Nanotechnol. 2009; 4(12): 781.

[4] Drexler KE. Engines of Creation. The Coming Era of Nanotechnology. New York, NY: Doubleday; 1986.

[5] Morigi V, Tocchio A, Bellavite Pellegrini C, Sakamoto JH, Arnone M, Tasciotti E. Nanotechnology in medicine: from inception to market domination. J Drug Deliv. 2012; 2012: 389485.

[6] Guo L, Yang J, Wang H, Yi Y. Multistage self-assembled nanomaterials for cancer immunotherapy. Molecules. 2023; 28(23): 7750.

[7] Abbasi S, Khademi S, Montazerabadi A, Sahebkar A. FAP-targeted nanoparticle-based imaging in cancer: a systematic review. J Biomed Phys Eng. 2024 1; 14(4): 323-334.

[8] Salih S, Elliyanti A, Alkatheeri A, AlYafei F, Almarri B, Khan H. The role of molecular imaging in personalized medicine. J Pers Med. 2023; 13(2): 369.

[9] Murciano-Goroff YR, Suehnholz SP, Drilon A, Chakravarty D. Precision oncology: 2023 in review. Cancer Discov. 2023; 13(12): 2525-2531.

[10] Liu Y, Xu Y, Li X, et al. Towards precision oncology discovery: four less known genes and their unknown interactions as highest-performed biomarkers for colorectal cancer. NPJ Precis Oncol. 2024; 8(1): 13.

[11] Hood L, Rowen L. The Human Genome Project: big science transforms biology and medicine. Genome Med. 2013; 5(9): 79.

[12] Mardis ER. The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harb Perspect Med. 2019; 9(9): a036269.

[13] Greco F, Panunzio A, Bernetti C, Tafuri A, Beomonte Zobel B, Mallio CA. The radiogenomic landscape of clear cell renal cell carcinoma: insights into lipid metabolism through evaluation of ADFP expression. Diagnostics (Basel). 2024; 14(15): 1667.

[14] The Cancer Genome Atlas homepage. http://cancergenome.nih.gov/abouttcga

[15] Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023; 29(7): 554-566.

[16] Hristova VA, Chan DW. Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev Proteomics. 2019; 16(2): 93-110.

[17] National Cancer Institute. List of Targeted Therapy Drugs Approved for Specific Types of Cancer. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/approved-drug-list

[18] Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1): 79.

[19] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20(11): 651-668.

[20] Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022; 3(8): 911-926.

[21] Perez-Lopez R, Reis-Filho JS, Kather JN. A framework for artificial intelligence in cancer research and precision oncology. NPJ Precis Oncol. 2023; 7(1): 43.

[22] Howard FM, Dolezal J, Kochanny S, et al. Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. NPJ Breast Cancer. 2023; 9(1): 25.

[23] Garg P, Pareek S, Kulkarni P, Salgia R, Singhal SS. Nanoengineering solutions for cancer therapy: bridging the gap between clinical practice and translational research. J Clin Med. 2024; 13(12): 3466.

[24] Maharana RL, Swain S, Mahapatra SK, Jena BR. Self-emulsifying drug delivery systems: concept to applications, regulatory issues, recent patents, current challenges and future directions. Curr Pharm Biotechnol. 2024.

[25] Tan P, Chen X, Zhang H, Wei Q, Luo K. Artificial intelligence aids in development of nanomedicines for cancer management. Semin Cancer Biol. 2023; 89: 61-75.

[26] Khazaei M, Hosseini MS, Haghighi AM, Misaghi M. Nanosensors and their applications in early diagnosis of cancer. Sens Bio-Sens Res. 2023; 41: 100569.

[27] Gan X, Qiu F, Yuan R, Xiang Y. Biobarcode and sequence-responsive DNA nanocapsules for label-free and sensitive electrochemical detection of circulating tumor cells. Sens Actuators B Chem. 2022; 368: 132207.

[28] Amir H, Subramanian V, Sornambikai S, Ponpandian N, Viswanathan C. Nitrogen-enhanced carbon quantum dots mediated immunosensor for electrochemical detection of HER2 breast cancer biomarker. Bioelectrochemistry. 2024; 155: 108589.

[29] Hauser J, Dale M, Beck O, et al. Microfluidic device for patient-centric multiplexed assays with readout in centralized laboratories. Anal Chem. 2023; 95(2): 1350-1358.

[30] Andoh V, Ocansey DKW, Naveed H, et al. The advancing role of nanocomposites in cancer diagnosis and treatment. Int J Nanomedicine. 2024; 19: 6099-6126.

[31] Truong TT, Mondal S, Doan VHM, et al. Precision-engineered metal and metal-oxide nanoparticles for biomedical imaging and healthcare applications. Adv Colloid Interface Sci. 2024; 332: 103263.

[32] Li Z, Lan J, Liu L, et al. Versatile thermo-sensitive liposomes with HSP inhibition and anti-inflammation for synergistic chemo-photothermal to inhibit breast cancer metastasis. Int J Pharm. 2024; 664: 124583.

[33] Beheshtizadeh N, Amiri Z, Tabatabaei SZ, et al. Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches. J Transl Med. 2024; 22(1): 520.

[34] Al-Taie A, Özcan Bülbül E. A paradigm use of monoclonal antibodies-conjugated nanoparticles in breast cancer treatment: current status and potential approaches. J Drug Target. 2024; 32(1): 45-56.

[35] Marques AC, Costa PC, Velho S, Amaral MH. Lipid nanoparticles functionalized with antibodies for anticancer drug therapy. Pharmaceutics. 2023; 15(1): 216.

[36] Chen J. Preparation of doxorubicin liposomes by remote loading method. Methods Mol Biol. 2023; 2622: 95-101.

[37] Chattha GM, Arshad S, Kamal Y, et al. Nanorobots: an innovative approach for DNA-based cancer treatment. J Drug Deliv Sci Technol. 2023; 13: 104173.

[38] Singh R, Deshmukh R. DNA nanobots - emerging customized nanomedicine in oncology. Curr Drug Deliv. 2023; 20(2): 111-126.

[39] Kong X, Gao P, Wang J, Fang Y, Hwang KC. Advances of medical nanorobots for future cancer treatments. J Hematol Oncol. 2023; 16(1): 74.

[40] Weng WH, Wang CY, Yan ZY, Lee HT, Kao CY, Chang CW. Isolation and characterizations of multidrug-resistant human cancer cells by a biodegradable nano-sensor. Biosens Bioelectron. 2024; 249: 115985.

[41] Premachandran S, Dhinakaran AK, Das S, Venkatakrishnan K, Tan B, Sharma M. Detection of lung cancer metastasis from blood using L-MISC nanosensor: Targeting circulating metastatic cues for improved diagnosis. Biosens Bioelectron. 2024; 243: 115782.

[42] Premachandran S, Haldavnekar R, Ganesh S, Das S, Venkatakrishnan K, Tan B. Self-functionalized superlattice nanosensor enables glioblastoma diagnosis using liquid biopsy. ACS Nano. 2023; 17(20): 19832-19852.

[43] Dogra P, Shinglot V, Ruiz-Ramírez J, et al. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer. Mol Cancer. 2024; 23(1): 156.

[44] Wang T, Russo DP, Demokritou P, et al. An online nanoinformatics platform empowering computational modeling of nanomaterials by nanostructure annotations and machine learning toolkits. Nano Lett. 2024; 24(33): 10228-10236.

[45] Dennahy IS, Han Z, MacCuaig WM, et al. Nanotheranostics for image-guided cancer treatment. Pharmaceutics. 2022; 14(5): 917.

[46] Al-Thani AN, Jan AG, Abbas M, Geetha M, Sadasivuni KK. Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review. Life Sci. 2024; 352(122899): 122899.

[47] Shukla A, Maiti P. Nanomedicine and versatile therapies for cancer treatment. MedComm. 2022; 3(3): e163.

[48] Bober Z, Bartusik-Aebisher D, Aebisher D. Application of dendrimers in anticancer diagnostics and therapy. Molecules. 2022; 27(10): 3237.

[49] Jiang Y, Lee J, Seo JM, Davaa E, Shin KJ, Yang SG. Enhanced thermodynamic, pharmacokinetic and theranostic properties of polymeric micelles via hydrophobic core-clustering of superparamagnetic iron oxide nanoparticles. Biomater Res. 2022; 26(1): 8.

[50] Junyaprasert VB, Thummarati P. Innovative design of targeted nanoparticles: Polymer-drug conjugates for enhanced cancer therapy. Pharmaceutics. 2023; 15(9).

[51] Wang Y, Xia H, Chen B, Wang Y. Rethinking nanoparticulate polymer-drug conjugates for cancer theranostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023; 15(1): e1828.

[52] Kundu P, Singh D, Singh A, Sahoo SK. Cancer nanotheranostics: a nanomedicinal approach for cancer therapy and diagnosis. Anticancer Agents Med Chem. 2020; 20(11): 1288-1299.

[53] Gawne PJ, Ferreira M, Papaluca M, Grimm J, Decuzzi P. New opportunities and old challenges in the clinical translation of nanotheranostics. Nat Rev Mater. 2023; 8: 783-798.

[54] Tang L, Xiao Q, Mei Y, et al. Insights on functionalized carbon nanotubes for cancer theranostics. J Nanobiotechnology. 2021; 19(1): 423.

[55] Sharma M, Alessandro P, Cheriyamundath S, Lopus M. Therapeutic and diagnostic applications of carbon nanotubes in cancer: recent advances and challenges. J Drug Target. 2024; 32(3): 287-299.

[56] Kommineni N, Chaudhari R, Conde J, et al. Engineered liposomes in interventional theranostics of solid tumors. ACS Biomater Sci Eng. 2023; 9(8): 4527-4557.

[57] German-Cortés J, Vilar-Hernández M, Rafael D, Abasolo I, Andrade F. Solid lipid nanoparticles: multitasking nano-carriers for cancer treatment. Pharmaceutics. 2023; 15(3).

[58] Bukhari SZ, Zeth K, Iftikhar M, et al. Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics. Curr Res Pharmacol Drug Discov. 2021; 2(100067): 100067.

[59] Naziris N, Demetzos C. Lipid nanoparticles as platforms for theranostic purposes: recent advances in the field. J Nanotheranostics. 2022; 3(2): 86-101.

[60] Gao Q, Zhang J, Gao J, Zhang Z, Zhu H, Wang D. Gold nanoparticles in cancer theranostics. Front Bioeng Biotechnol. 2021; 9: 647905.

[61] Dastgheib ZS, Abolmaali SS, Farahavar G, Salmanpour M, Tamaddon AM. Gold nanostructures in melanoma: advances in treatment, diagnosis, and theranostic applications. Heliyon. 2024; 10(15): e35655.

[62] Qureshi S, Anjum S, Hussain M, et al. A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy. Int J Pharm. 2024; 660(124301): 124301.

[63] Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011; 44(10): 883-892.

[64] Gauger AJ, Hershberger KK, Bronstein LM. Theranostics based on magnetic nanoparticles and polymers: intelligent design for efficient diagnostics and therapy. Front Chem. 2020; 8: 561.

[65] Baeza A, Vallet-Regí M. Mesoporous silica nanoparticles as theranostic antitumoral nanomedicines. Pharmaceutics. 2020; 12(10): 957.

[66] Tripathi SK, Kaur G, Khurana RK, Kapoor S, Singh B. Quantum dots and their potential role in cancer theranostics. Crit Rev Ther Drug Carrier Syst. 2015; 32(6): 461-502.

[67] Khan MS, Sheikh A, Abourehab MAS, Gupta N, Kesharwani P. Understanding the theranostic potential of quantum dots in cancer management. Mater Today Commun. 2023; 36(106424): 106424.

[68] Kobayashi Y, Kushihara Y, Saito N, Yamaguchi S, Kakimi K. A novel scoring method based on RNA-Seq immunograms describing individual cancer-immunity interactions. Cancer Sci. 2020; 111(11): 4031-4040.

[69] Jahangir CA, Page DB, Broeckx G, et al. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer. J Pathol. 2024; 262(3): 271-288.

[70] Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res. 2019; 52(6): 1543-1554.

[71] Park H, Lee S, Son MK, et al. Targeted liposomal co-delivery of an immunogenic cell death inducer and a Toll-like receptor 4 agonist for enhanced cancer chemo-immunotherapy. ACS Appl Mater Interfaces. 2024; 16(32): 41810-41818.

[72] Hu XX, He PP, Qi GB, et al. Transformable nanomaterials as an artificial extracellular matrix for inhibiting tumor invasion and metastasis. ACS Nano. 2017; 11(4): 4086-4096.

[73] Jin Y, Huang Y, Ren H, et al. Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment. Biomaterials. 2024; 305: 122463.

[74] Bhamidipati K, Malleswara Rao Nakka N, Ahmed M, et al. Enhancing cancer immunotherapy with mannose mimicking glycopolymer nanoparticles induced activation of dendritic cells. Bioorg Chem. 2024; 152: 107711.

[75] Schlich M, D’Apice L, Lai F et al. Boosting antigen-specific T cell activation with lipid-stabilized protein nanoaggregates. Int J Pharm. 2024; 661: 124404.

[76] Li Z, Liu X, Cai N, et al. Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy. Cancer Lett. 2024; 599: 217152.

[77] Wang B, Cui H, Kiessling F, Lammers T, Baumjohann D, Shi Y. Targeting intracellular and extracellular receptors with nano-to-macroscale biomaterials to activate immune cells. J Control Release. 2023; 357: 52-66.

[78] Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges. Nanoscale Res Lett. 2021; 16(1): 173.

[79] Wang J, Guo B, Sun Z, et al. Polymersomal poly(I:C) self-magnifies antitumor immunity by inducing immunogenic cell death and systemic immune activation. Adv Healthc Mater. 2024:e2400784.

[80] Mohammadzadeh V, Rahiman N, Cabral H, et al. Poly-γ-glutamic acid nanoparticles as adjuvant and antigen carrier system for cancer vaccination. J Control Release. 2023; 362: 278-296.

[81] Li L, Ma B, Wang W. Peptide-based nanomaterials for tumor immunotherapy. Molecules. 2020; 26(1): 132.

[82] Li K, Liu CJ, Zhang XZ. Multifunctional peptides for tumor therapy. Adv Drug Deliv Rev. 2020; 160: 36-51.

[83] Ma C, Cheng Z, Tan H, et al. Nanomaterials: leading immunogenic cell death-based cancer therapies. Front Immunol. 2024; 15: 1447817.

[84] Yao R, Xie C, Xia X. Recent progress in mRNA cancer vaccines. Hum Vaccin Immunother. 2024; 20(1): 2307187.

[85] Cai T, Liu H, Zhang S, Hu J, Zhang L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. J Nanobiotechnology. 2021; 19(1): 389.

[86] Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2020; 6(7): 1973-1987.

[87] Isser A, Silver AB, Pruitt HC, et al. Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy. Nat Commun. 2022; 13(1): 6086.

[88] Zhou Y, Que KT, Tang HM, Zhang P, Fu QM, Liu ZJ. Anti-CD206 antibody-conjugated Fe3O4-based PLGA nanoparticles selectively promote tumor-associated macrophages to polarize to the pro-inflammatory subtype. Oncol Lett. 2020; 20(6): 298.

[89] Yu C, Jiang W, Li B, Hu Y, Liu D. The role of integrins for mediating nanodrugs to improve performance in tumor diagnosis and treatment. Nanomaterials (Basel). 2023; 13(11): 1721.

[90] Cheng TM, Chang WJ, Chu HY, et al. Nano-strategies targeting the integrin αvβ3 network for cancer therapy. Cells. 2021; 10(7): 1684.

[91] Glass EB, Hoover AA, Bullock KK, et al. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer. 2022; 22(1): 497.

[92] Fu Z, Xiang J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. Int J Mol Sci. 2020; 21(23): 9123.

[93] Camorani S, Tortorella S, Agnello L, et al. Aptamer-functionalized nanoparticles mediate PD-L1 siRNA delivery for effective gene silencing in triple-negative breast cancer cells. Pharmaceutics. 2022; 14(10): 2225.

[94] Jiang Q, Yao F, An Y, et al. Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers. Cancer Nanotechnol. 2024; 15(1).

[95] Cruz LJ, Rueda F, Cordobilla B, et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm. 2011; 8(1): 104-116.

[96] Sui C, Wu H, Li X, et al. Cancer immunotherapy and its facilitation by nanomedicine. Biomark Res. 2024; 12(1): 77.

[97] Kiaie SH, Salehi-Shadkami H, Sanaei MJ, et al. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. J Nanobiotechnology. 2023; 21(1): 339.

[98] Qiu Y, Su M, Liu L, Tang Y, Pan Y, Sun J. Clinical application of cytokines in cancer immunotherapy. Drug Des Dev. Ther. 2021; 15: 2269-2287.

[99] Lian H, Ma S, Zhao D, et al. Cytokine therapy combined with nanomaterials participates in cancer immunotherapy. Pharmaceutics. 2022; 14(12): 2606.

[100] Tarhini AA, Gogas H, Kirkwood JM. IFN-α in the treatment of melanoma. J Immunol. 2012; 189(8): 3789-3793.

[101] Qureshi M, Viegas C, Duarte SOD, Girardi M, Shehzad A, Fonte P. Camptothecin-loaded mesoporous silica nanoparticles functionalized with CpG oligodeoxynucleotide as a new approach for skin cancer treatment. Int J Pharm. 2024; 660: 124340.

[102] Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020; 20(6): 375-388.

[103] van Leent MMT, Priem B, Schrijver DP, et al. Regulating trained immunity with nanomedicine. Nat Revi Mater. 2022; 7(6): 465-481.

[104] Makharadze D, Kantaria T, Yousef I, Del Valle LJ, Katsarava R, Puiggalí J. PEGylated micro/nanoparticles based on biodegradable poly(ester amides): preparation and study of the core-shell structure by synchrotron radiation-based FTIR microspectroscopy and electron microscopy. Int J Mol Sci. 2024; 25(13): 6999.

[105] Reichel D, Tripathi M, Perez JM. Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment. Nanotheranostics. 2019; 3(1): 66-88.

[106] Lee D, Huntoon K, Lux J, Kim BYS, Jiang W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nat Rev Bioeng. 2023; 1: 499-517.

[107] Guevara ML, Persano F, Persano S. Nano-immunotherapy: Overcoming tumour immune evasion. Semin Cancer Biol. 2021; 69: 238-248.

[108] Sun L, Liu H, Ye Y, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023; 8(1): 418.

[109] Innovative Genomics Institute. CRISPR Clinical Trials: A 2022 Update. https://innovativegenomics.org/news/crispr-clinical-trials-2022

[110] Morshedzadeh F, Ghanei M, Lotfi M, et al. An update on the application of CRISPR technology in clinical practice. Mol Biotechnol. 2024; 66(2): 179-197.

[111] Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022; 22(5): 259-279.

[112] Yan J, Kang DD, Dong Y. Harnessing lipid nanoparticles for efficient CRISPR delivery. Biomater Sci. 2021; 9(18): 6001-6011.

[113] Zhen S, Li X. Liposomal delivery of CRISPR/Cas9. Cancer Gene Ther. 2020; 27(7-8): 515-527.

[114] Qin Y, Ou L, Zha L, Zeng Y, Li L. Delivery of nucleic acids using nanomaterials. Mol Biomed. 2023; 4(1): 48.

[115] Sun Z, Ren Y, Zhu W, Xiao Y, Wu H. DNA nanotechnology-based nucleic acid delivery systems for bioimaging and disease treatment. Analyst. 2024; 149(3): 599-613.

[116] Zhang H, Qin C, An C, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer. 2021; 20(1): 126.

[117] Khodakarami A, Adibfar S, Karpisheh V, et al. The molecular biology and therapeutic potential of Nrf2 in leukemia. Cancer Cell Int. 2022; 22(1): 241.

[118] Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, et al. CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett. 2022; 27: 49.

[119] Shen Z, Yu N, Zhang Y, et al. The potential roles of HIF-1α in epithelial-mesenchymal transition and ferroptosis in tumor cells. Cell Signal. 2024; 122: 111345.

[120] Bao YY, Zhong JT, Shen LF, et al. Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway. J Cell Mol Med. 2022; 26(10): 2881-2894.

[121] Wahiduzzaman M, Karnan S, Ota A, et al. Establishment and characterization of CRISPR/Cas9-mediated NF2-/-human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. Cancer Sci. 2019; 110(1): 180-193.

[122] Moses C, Nugent F, Waryah CB, Garcia-Bloj B, Harvey AR, Blancafort P. Activating PTEN tumor suppressor expression with the CRISPR/dCas9 system. Mol Ther Nucleic Acids. 2019; 14: 287-300.

[123] Wan T, Pan Q, Liu C, et al. A duplex CRISPR-Cas9 ribonucleoprotein nanomedicine for colorectal cancer gene therapy. Nano Lett. 2021; 21(22): 9761-9771.

[124] Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR/Cas9 for cancer research and therapy. Semin Cancer Biol. 2019; 55: 106-119.

[125] Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022; 21(1): 78.

[126] Chattopadhyay S, Hazra R, Mallick A, Gayen S, Roy S. Small-molecule in cancer immunotherapy: revolutionizing cancer treatment with transformative, game-changing breakthroughs. Biochim Biophys Acta Rev Cancer. 2024; 1879(5): 189170.

[127] Sorrentino C, D’Antonio L, Ciummo SL, et al. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality. J Hematol Oncol. 2022; 15(1): 145.

[128] D’Antonio L, Fieni C, Ciummo SL, et al. Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival. J Immunother Cancer. 2023; 11(3): e006056.

[129] Graham DB, Root DE. Resources for the design of CRISPR gene editing experiments. Genome Biol. 2015; 16(1): 260.

[130] Mei Y, Wang Y, Chen H, Sun ZS, Ju XD. Recent progress in CRISPR/Cas9 technology. J Genet Genomics. 2016; 43(2): 63-75.

[131] Nishimasu H, Ran FA, Hsu PD, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014; 156(5): 935-949.

[132] Naeem M, Alkhnbashi OS. Current bioinformatics tools to optimize CRISPR/Cas9 experiments to reduce off-target effects. Int J Mol Sci. 2023; 24(7): 6261.

[133] Liu M, Rehman S, Tang X, et al. Methodologies for improving HDR efficiency. Front Genet. 2018; 9: 691.

[134] Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024; 23(1): 9.

[135] Li T, Yang Y, Qi H, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023; 8(1): 36.

[136] Allemailem KS, Almatroodi SA, Almatroudi A, et al. Recent advances in genome-editing technology with CRISPR/Cas9 variants and stimuli-responsive targeting approaches within tumor cells: a future perspective of cancer management. Int J Mol Sci. 2023; 24(8): 7052.

[137] Duan L, Ouyang K, Xu X, et al. Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front Genet. 2021; 12: 673286.

[138] Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020; 11(1): 3232.

[139] Rosenblum D, Gutkin A, Kedmi R, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020; 6(47): eabc9450.

[140] Jo A, Ringel-Scaia VM, McDaniel DK, et al. Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid. J Nanobiotechnology. 2020; 18(1): 16.

[141] Lv H, Zhu Q, Liu K, et al. Coupling of a bifunctional peptide R13 to OTMCS-PEI copolymer as a gene vector increases transfection efficiency and tumor targeting. Int J Nanomedicine. 2014; 9: 1311-1322.

[142] Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Front Bioeng Biotechnol. 2022; 10: 895713.

[143] Yang S, Wu Q, Wei Y, Gong C. CRISPR-Cas9 delivery by artificial virus (RRPHC). In: Methods in Molecular Biology. Methods in molecular biology (Clifton, N.J.). Springer New York; 2019: 81-91.

[144] Chen C, Zhong W, Du S, et al. Intelligent nanotherapeutic strategies for the delivery of CRISPR system. Acta Pharm Sin B. 2023; 13(6): 2510-2543.

[145] Mohammadian Farsani A, Mokhtari N, Nooraei S, et al. Lipid nanoparticles: the game-changer in CRISPR-Cas9 genome editing. Heliyon. 2024; 10(2): e24606.

[146] Kazemian P, Yu SY, Thomson SB, Birkenshaw A, Leavitt BR, Ross CJD. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol Pharm. 2022; 19(6): 1669-1686.

[147] Linnik DS, Tarakanchikova YV, Zyuzin MV, et al. Layer-by-Layer technique as a versatile tool for gene delivery applications. Expert Opin Drug Deliv. 2021; 18(8): 1047-1066.

[148] Tang H, Zhao X, Jiang X. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing. Adv Drug Deliv Rev. 2021; 168: 55-78.

[149] Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Theranostics. 2021; 11(2): 614-648.

[150] Li J, Wang Q, Xia G, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics. 2023; 15(9): 2233.

[151] Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther. 2023; 8(1): 1.

[152] Javid H, Oryani MA, Rezagholinejad N, Esparham A, Tajaldini M, Karimi-Shahri M. RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions. Cancer Med. 2024; 13(2): e6800.

[153] Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10(1): 9-22.

[154] Ibrahim MAI, Othman R, Chee CF, Ahmad Fisol F. Evaluation of folate-functionalized nanoparticle drug delivery systems-effectiveness and concerns. Biomedicines. 2023; 11(7).

[155] Colombo E, Coppini DA, Maculan S, et al. Folic acid functionalization for targeting self-assembled paclitaxel-based nanoparticles. RSC Adv. 2022; 12(54): 35484-35493.

[156] Urano Y, Asanuma D, Hama Y, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med. 2009; 15(1): 104-109.

[157] Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017; 46(12): 3830-3852.

[158] Sun H, Li X, Liu Q, Sheng H, Zhu L. pH-responsive self-assembled nanoparticles for tumor-targeted drug delivery. J Drug Target. 2024; 32(6): 672-706.

[159] Blümler P. Magnetic guiding with permanent magnets: concept, realization and applications to nanoparticles and cells. Cells. 2021; 10(10): 2708.

[160] Tombácz E, Turcu R, Socoliuc V, Vékás L. Magnetic iron oxide nanoparticles: recent trends in design and synthesis of magnetoresponsive nanosystems. Biochem Biophys Res Commun. 2015; 468(3): 442-453.

[161] Thang DC, Wang Z, Lu X, Xing B. Precise cell behaviors manipulation through light-responsive nano-regulators: recent advance and perspective. Theranostics. 2019; 9(11): 3308-3340.

[162] Wang F, Duan H, Xu W, Sheng G, Sun Z, Chu H. Light-activated nanomaterials for tumor immunotherapy. Front Chem. 2022; 10: 1031811.

[163] Guo S, Song Z, Ji DK, et al. Combined photothermal and photodynamic therapy for cancer treatment using a multifunctional graphene oxide. Pharmaceutics. 2022; 14(7): 1365.

[164] Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020; 20: 16.

[165] Matas J, Kohrn B, Fredrickson J, et al. Colorectal cancer is associated with the presence of cancer driver mutations in normal colon. Cancer Res. 2022; 82(8): 1492-1502.

[166] US National Library of Medicine. http://www.clinicaltrials.gov

[167] Stefanoudakis D, Kathuria-Prakash N, Sun AW, et al. The potential revolution of cancer treatment with CRISPR technology. Cancers (Basel). 2023; 15(6): 1813.

[168] Nie D, Guo T, Yue M, et al. Research progress on nanoparticles-based CRISPR/Cas9 system for targeted therapy of tumors. Biomolecules. 2022; 12(9): 1239.

[169] Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022; 23(8): 467-491.

[170] Luo Y, Li X, Zhao Y, Zhong W, Xing M, Lyu G. Development of organs-on-chips and their impact on precision medicine and advanced system simulation. Pharmaceutics. 2023; 15(8): 2094.

[171] Zhang L, Liao W, Chen S, et al. Towards a New 3Rs Era in the construction of 3D cell culture models simulating tumor microenvironment. Front Oncol. 2023; 13: 1146477.

[172] Leung CM, de Haan P, Ronaldson-Bouchard K, et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers. 2022; 2: 33.

[173] Fieni C, Ciummo SL, Sorrentino C, et al. Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing. Mol Ther. 2024:S1525-0016(24)00596-3.

[174] Liu X, Su Q, Zhang X, et al. Recent advances of organ-on-a-chip in cancer modeling research. Biosensors (Basel). 2022; 12(11): 1045.

[175] Farhang Doost N, Srivastava SK. A comprehensive review of organ-on-a-chip technology and its applications. Biosensors (Basel). 2024; 14(5): 225.

[176] Chen H, Luo Z, Lin X, Zhu Y, Zhao Y. Sensors-integrated organ-on-a-chip for biomedical applications. Nano Res. 2023: 1-28.

[177] Hwangbo H, Chae S, Kim W, Jo S, Kim GH. Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues. Theranostics. 2024; 14(1): 33-55.

[178] Carvalho V, Bañobre-López M, Minas G, Teixeira SFCF, Lima R, Rodrigues RO. The integration of spheroids and organoids into organ-on-a-chip platforms for tumour research: a review. Bioprinting. 2022; 27: e00224.

[179] Zhang Y, Wang D, Peng M, et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021; 40(1): 81.

[180] Marzagalli M, Pelizzoni G, Fedi A, et al. A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model. Front Bioeng Biotechnol. 2022; 10: 945149.

[181] Krüger M, Kopp S. Tumor models and drug targeting in vitro-where are we today? Where do we go from here? Cancers (Basel). 2023; 15(6): 1768.

[182] Jouybar M, de Winde CM, Wolf K, Friedl P, Mebius RE, den Toonder JMJ. Cancer-on-chip models for metastasis: importance of the tumor microenvironment. Trends Biotechnol. 2024; 42(4): 431-448.

[183] Hoseini B, Jaafari MR, Golabpour A, Rahmatinejad Z, Karimi M, Eslami S. Machine learning-driven advancements in liposomal formulations for targeted drug delivery: a narrative literature review. Curr Drug Deliv. 2024.

[184] Guenat OT, Geiser T, Berthiaume F. Clinically relevant tissue scale responses as new readouts from organs-on-a-chip for precision medicine. Annu Rev Anal Chem (Palo Alto Calif). 2020; 13(1): 111-133.

[185] Rodríguez F, Caruana P, De la Fuente N, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022; 12(6): 784.

[186] Chauhan S, Nagpal K. Latest delivery advancements of lipid nanoparticles for cancer treatment. Assay Drug Dev Technol. 2024; 22(6): 340-360.

[187] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20(2): 101-124.

[188] Sharma S, Chakraborty M, Yadav D, et al. Strategic developments in polymer-functionalized liposomes for targeted colon cancer therapy: an updated review of clinical trial data and future horizons. Biomacromolecules. 2024; 25(9): 5650-5669.

[189] Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023; 24(7): 6615.

[190] Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020; 3(4): 930-946.

[191] Mugundhan SL, Mohan M. Nanoscale strides: exploring innovative therapies for breast cancer treatment. RSC Adv. 2024; 14(20): 14017-14040.

[192] Xiao X, Teng F, Shi C, et al. Polymeric nanoparticles-Promising carriers for cancer therapy. Front Bioeng Biotechnol. 2022; 10: 1024143.

[193] Pednekar PP, Godiyal SC, Jadhav KR, Kadam VJ. Chapter 23 - Mesoporous silica nanoparticles: a promising multifunctional drug delivery system. In: Ficai A, Grumezescu AM, eds. Micro and Nano Technologies, Nanostructures for Cancer Therapy. Amsterdam, NL: Elsevier; 2017: 593-621.

[194] Escriche-Navarro B, Escudero A, Lucena-Sánchez E, Sancenón F, García-Fernández A, Martínez-Máñez R. Mesoporous silica materials as an emerging tool for cancer immunotherapy. Adv Sci (Weinh). 2022; 9(26): e2200756.

[195] Cavallaro PA, De Santo M, Belsito EL, et al. Peptides targeting HER2-positive breast cancer cells and applications in tumor imaging and delivery of chemotherapeutics. Nanomaterials (Basel). 2023; 13(17): 2476.

[196] Pires ICB, Shuchi SI, Tostes BVA, et al. Theranostics using MCM-41-based mesoporous silica nanoparticles: integrating magnetic resonance imaging and novel chemotherapy for breast cancer treatment. Int J Mol Sci. 2024; 25(15): 8097.

[197] Crintea A, Motofelea AC, Şovrea AS, et al. Dendrimers: advancements and potential applications in cancer diagnosis and treatment—an overview. Pharmaceutics. 2023; 15(5): 1406.

[198] Kesharwani P, Ma R, Sang L et al. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023; 22(1): 98.

[199] Hammond SM, Aartsma-Rus A, Alves S, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021; 13(4): e13243.

[200] Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022; 23(5): 265-280.

[201] Fieni C, Sorrentino C, Ciummo SL, et al. Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival. Exp Mol Med. 2024.

[202] Eloy JO, Petrilli R, Trevizan LNF, Chorilli M. Immunoliposomes: a review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces. 2017; 159: 454-467.

[203] Xu S, Zhang G, Zhang J, Liu W, Wang Y, Fu X. Advances in brain tumor therapy based on the magnetic nanoparticles. Int J Nanomedicine. 2023; 18: 7803-7823.

[204] Zhu J, Wang J, Li Y. Recent advances in magnetic nanocarriers for tumor treatment. Biomed Pharmacother. 2023; 159: 114227.

[205] Huang T, Peng L, Han Y, et al. Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front Immunol. 2022; 13: 922301.

[206] Shi T, Sun M, Lu C, Meng F. Self-assembled nanoparticles: a new platform for revolutionizing therapeutic cancer vaccines. Front Immunol. 2023; 14: 1125253.

[207] Gurunathan S, Thangaraj P, Wang L, Cao Q, Kim JH. Nanovaccines: an effective therapeutic approach for cancer therapy. Biomed Pharmacother. 2024; 170: 115992.

[208] Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond). 2019; 14(1): 93-126.

[209] Nirmala MJ, Kizhuveetil U, Johnson AGB, Nagarajan R, Muthuvijayan V. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead. RSC Adv. 2023; 13(13): 8606-8629.

[210] Nawaz W, Xu S, Li Y, Huang B, Wu X, Wu Z. Nanotechnology and immunoengineering: how nanotechnology can boost CAR-T therapy. Acta Biomater. 2020; 109: 21-36.

[211] Chuang ST, Conklin B, Stein JB, Pan G, Lee KB. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. Nano Converg. 2022; 9(1): 19.

[212] Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022; 13: 927153.

[213] Zuo YH, Zhao XP, Fan XX. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor. Pharmacol Res. 2022; 184: 106454.

[214] Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022; 21(7): 495-508.

[215] Ouled Ltaief O, Ben Amor I, Hemmami H, et al. Recent developments in cancer diagnosis and treatment using nanotechnology. Ann Med Surg (Lond). 2024; 86(8): 4541-4554.

[216] Parveen S, Abira R, Paikray S, Sahoo L, Tripathy NS, Dilnawaz F. Recent advancement of nanotheranostics in cancer applications. Curr Drug Deliv. 2024.

[217] Zeng Y, Gao Y, He L, et al. Smart delivery vehicles for cancer: categories, unique roles and therapeutic strategies. Nanoscale Adv. 2024; 6(17): 4275-4308.

[218] Mendes LP, Lima EM, Torchilin VP. Chapter 9 - Targeted nanotheranostics for selective drug delivery in cancer. In: Conde J, ed. Handbook of Nanomaterials for Cancer Theranostics. Amsterdam, NL: Elsevier; 2018: 245-277.

[219] Domb AJ, Sharifzadeh G, Nahum V, Hosseinkhani H. Safety evaluation of nanotechnology products. Pharmaceutics. 2021; 13(10): 1615.

[220] Egwu CO, Aloke C, Onwe KT, et al. Nanomaterials in drug delivery: strengths and opportunities in medicine. Molecules. 2024; 29(11): 2584.

[221] Eker F, Duman H, Akdaşçi E, et al. A comprehensive review of nanoparticles: from classification to application and toxicity. Molecules. 2024; 29(15): 3482.

[222] Oualikene-Gonin W, Sautou V, Ezan E, et al. Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products. Front Public Health. 2023; 11: 1125577.

[223] Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020; 8(17): 4653-4664

[224] U.S. Food & Drug Administration. Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry

[225] Costello RA, Genetic data and the right to privacy: towards a relational theory of privacy? Hum Rights Law Rev. 2022; 22(1): ngab031.

[226] Souto EB, Blanco-Llamero C, Krambeck K et al. Regulatory insights into nanomedicine and gene vaccine innovation: safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024; 180: 1-17.

[227] Mahmud MM, Pandey N, Winkles JA, Woodworth GF, Kim AJ. Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials. Nano Today. 2024; 56: 102314.

[228] Liu Y, Liang Y, Yuhong J, et al. Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs. Drug Des Devel Ther. 2024; 18: 1469-1495.

[229] Sivasubramanian M, Lin LJ, Wang YC, Yang CS, Lo LW. Industrialization’s eye view on theranostic nanomedicine. Front Chem. 2022; 10: 918715.

[230] Giri PM, Banerjee A, Layek B. A recent review on cancer nanomedicine. Cancers (Basel). 2023; 15(8): 2256.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.